Key Points
- CFO Alex Thurman sold 1,521 shares on March 24 at an average price of $105.24 for a total of $160,070.04, trimming his stake by 3.17% to 46,498 shares; the trade was disclosed on an SEC Form 4.
- Shares were trading up about 4% (opened $109.48) within a 52‑week range of $73.16–$130.23; Glaukos has a $6.36B market cap, a negative P/E, and strong liquidity metrics (debt/equity 0.10, quick ratio 4.06).
- Glaukos missed quarterly EPS (-$0.28 vs. -$0.22) but reported revenue up 35.6% YoY to $143.12M, and analysts remain largely positive with an average target of about $133.69 and most ratings at "Buy" or "Moderate Buy."
Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 1,521 shares of Glaukos stock in a transaction that occurred on Tuesday, March 24th. The stock was sold at an average price of $105.24, for a total transaction of $160,070.04. Following the transaction, the chief financial officer directly owned 46,498 shares in the company, valued at $4,893,449.52. This trade represents a 3.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Glaukos Trading Up 4.0%
Shares of GKOS opened at $109.48 on Thursday. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $130.23. The firm has a market cap of $6.36 billion, a price-to-earnings ratio of -33.58 and a beta of 0.70. The firm has a 50 day moving average price of $113.41 and a 200-day moving average price of $101.77. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.06 and a current ratio of 4.69.
Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. Glaukos's revenue for the quarter was up 35.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.40) EPS. As a group, equities research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.
Institutional Investors Weigh In On Glaukos
Large investors have recently made changes to their positions in the business. UMB Bank n.a. raised its holdings in shares of Glaukos by 102.6% during the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 158 shares in the last quarter. First Horizon Corp lifted its stake in Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 223 shares during the period. Los Angeles Capital Management LLC bought a new stake in Glaukos in the fourth quarter valued at $28,000. Larson Financial Group LLC increased its position in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after purchasing an additional 132 shares during the period. Finally, REAP Financial Group LLC bought a new position in Glaukos in the 3rd quarter worth $40,000. 99.04% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the company. Stifel Nicolaus raised their price target on Glaukos from $115.00 to $160.00 and gave the stock a "buy" rating in a research report on Thursday, January 22nd. Citigroup raised their target price on shares of Glaukos from $113.00 to $125.00 and gave the stock a "buy" rating in a report on Thursday, December 11th. UBS Group lifted their target price on shares of Glaukos from $140.00 to $145.00 and gave the stock a "buy" rating in a research note on Tuesday, December 23rd. Stephens upped their price target on shares of Glaukos from $115.00 to $145.00 and gave the company an "overweight" rating in a report on Friday, January 2nd. Finally, Piper Sandler reissued an "overweight" rating and set a $165.00 price target on shares of Glaukos in a research report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Glaukos currently has an average rating of "Moderate Buy" and an average target price of $133.69.
View Our Latest Report on Glaukos
About Glaukos
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
